Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maximilian Merz has a total of 146 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Analyzing Longitudinal wb-MRI Data and Clinical Course in a Cohort of Former Smoldering Multiple Myeloma Patients: Connections between MRI Findings and Clinical Progression Patterns

    by Markus Wennmann, Thomas Hielscher, Laurent Kintzelé, Bjoern H. Menze, Georg Langs, Maximilian Merz, Sandra Sauer, Hans-Ulrich Kauczor, Heinz-Peter Schlemmer, Stefan Delorme, et al.

    The purpose of this study was to analyze size and growth dynamics of focal lesions (FL) as well as to quantify diffuse infiltration (DI) in untreated smoldering multiple myeloma (SMM) patients and correlate those MRI features with timepoint and cause of progression. We investigated 199 whole-body magnetic resonance imaging (wb-MRI) scans originating from longitudinal imaging of 60 SMM patients and 39 computed tomography (CT) scans for corresponding osteolytic lesions (OL) in 17 patients. All FLs >5 mm were manually segmented to quantify volume and growth dynamics, and DI was scored, rating four compartments separately in T1- and fat-saturated T2-weighted images. The majority of patients with at least two FLs showed substantial spatial heterogeneity in growth dynamics. The volume of the largest FL (p = 0.001, c-index 0.72), the speed of growth of the fastest growing FL (p = 0.003, c-index 0.75), the DI score (DIS, p = 0.014, c-index 0.67), and its dynamic over time (DIS dynamic, p < 0.001, c-index 0.67) all significantly correlated with the time to progression. Size and growth dynamics of FLs correlated significantly with presence/appearance of OL in CT within 2 years after the respective MRI assessment (p = 0.016 and p = 0.022). DIS correlated with decrease of hemoglobin (p < 0.001). In conclusion, size and growth dynamics of FLs correlate with prognosis and local bone destruction. Connections between MRI findings and progression patterns (fast growing FL—OL; DIS—hemoglobin decrease) might enable more precise diagnostic and therapeutic approaches for SMM patients in the future.


  • Open Access

    Spatial Distribution of Focal Lesions in Whole-Body MRI and Influence of MRI Protocol on Staging in Patients with Smoldering Multiple Myeloma According to the New SLiM-CRAB-Criteria

    by Markus Wennmann, Thomas Hielscher, Laurent Kintzelé, Bjoern H. Menze, Georg Langs, Maximilian Merz, Sandra Sauer, Hans-Ulrich Kauczor, Heinz-Peter Schlemmer, Stefan Delorme, et al.

    The purpose of this study was to assess how different MRI protocols (spinal vs. spinal plus pelvic vs. whole-body (wb)-MRI) affect staging in patients with smoldering multiple myeloma (SMM), according to the SLiM-CRAB-criterion ‘>1 focal lesion (FL) in MRI’. In this retrospective study, a baseline cohort of 147 SMM patients with wb-MRI at initial diagnosis was investigated, including prognostic data regarding development of CRAB-criteria. Fifty-two patients formed a follow-up cohort with a median of three wb-MRIs. The locations of all FLs were determined and it was calculated how staging decisions regarding the criterion ‘>1 FL in MRI’ would have been made if only a limited anatomic area (spine vs. spine plus pelvis) would have been covered by the MRI protocol. Furthermore, subgroups of patients selected by different cutoff-protocol-combinations were compared regarding their prognosis for development of CRAB-criteria. With an MRI protocol limited to spine/spine plus pelvis, only 28%/64% of patients who actually had >1 FL in wb-MRI would have been rated correctly as having ‘>1 FL in MRI’. Fifty-four percent/36% of patients with exactly 1 FL in spine/spine plus pelvis revealed >1 FL when the entire wb-MRI was analyzed. During follow-up, four more patients developed >1 FL in wb-MRI; both limited MRI protocols would have detected only one of these four patients as having >1 FL at the correct timepoint. Having >1 FL in spine/in spine plus pelvis/in the whole body was associated with a 43%/57%/49% probability of developing CRAB-criteria within 2 years. Patients with >3 FL in spine plus pelvis and patients with >4 FL in the whole body had an 80% probability to develop CRAB-criteria within 2 years. MRI protocols limited to the spine or to spine plus pelvis lead to substantial underdiagnoses of patients who actually have >1 FL in wb-MRI at baseline and during follow-up, which influences staging and treatment decisions according to the current SLiM-CRAB criteria. However, given the spatial distribution of FLs and the analysis on clinical course of patients indicates that the cutoff for the number of FLs should be adopted according to the MRI protocol when using MRI for staging in SMM.


  • Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects

    by Lina Jansen, Maximilian Merz, Monika Engelhardt, Katja Weisel, Christof Scheid, Christian Straka, Christian Langer, Hans Salwender, Hermann Einsele, Nikolaus Kröger, et al.

    Evidence on volume outcome associations for autologous stem cell transplantation (ASCT) in multiple myeloma (MM) is limited. We investigated ASCT utilization patterns and volume outcome associations in the German National Registry for Stem Cell Transplants (DRST). MM patients with an upfront ASCT between 1998 and 2014 registered in the DRST were included. ASCT utilization increased strongly from 6% to 17% between 1999 and 2013 with the largest increase for patients aged 60–64 years (8–34%). The mean number of ASCTs conducted in the hospitals per year varied (quintiles, Q1:0.0–8.2 to Q5:31.0–102.7). Center volume was not associated with survival after upfront ASCT (lowest vs. highest center volume, hazard ratios and 95% confidence intervals: 0.95 (0.76–1.18), p = 0.92). Our findings may reflect a high standard of care and degree of specialization of centers performing ASCT for MM in Germany.


  • Einfluss des MRT-Bildgebungsprotokolls auf das Staging und folglich Therapieindikation bei Patienten mit Smoldering Myelom nach den neuen SLiM-CRAB-Kriterien

    by M Wennmann, L Kintzelé, T Hielscher, M Piraud, B Menze, H Kauczor, M Merz, J Hillengass, G Langs, M Weber

    Zielsetzung Nach den neuen SLiM-CRAB-Kriterien sind Patienten mit Smoldering Multiplem Myelom (SMM) mit >1 fokalen Läsion (FL) in der MRT zum Multiplen Myelom hochzustufen und systemisch zu therapieren. Zur Bildgebung wird primär Ganzkörper (GK)-MRT empfohlen, aufgrund der geringen Verfügbarkeit werden MRT der Wirbelsäule (WS) oder von WS und Becken (WS+B) als akzeptable Alternativen genannt. Ziel der Studie war zu untersuchen, wie sich die Wahl des Bildgebungsprotokolls auf das Staging von SMM Patienten nach dem Kriterium >1FL im MRT und damit auf die Therapieindikation auswirkt. Material und Methoden Die Studie wurde an 226 GK-MRT von 60 Patienten mit SMM durchgeführt. Alle Bildgebungen wurden an zwei 1,5-Tesla-Scannern vorgenommen und enthielten koronare T1-tse und STIR Sequenzen sowie sagittale T1-tse und T2* Sequenzen der Wirbelsäule. Für alle FL >=5mm wurden die Lokalisationen erfasst und es wurde simuliert, welche FL in welchem limitierten Protokoll (WS vs. WS+B) zur Darstellung gekommen wären. Ergebnisse 54% bzw. 46% der Bildgebungen, die in der GK-MRT >1FL zeigten, wären bei WS bzw. WS+B MRT nicht korrekt mit >1FL bewertet worden. Bei Bildgebungen ohne FL in der WS/WS+B MRT wird pro 12 /17 Erweiterungen zum GK-MRT ein weiterer Fall mit >1FL bewertet, in der Gruppe mit exakt 1FL im limitierten Protokoll wird dagegen fast jeder zweite Fall durch ein GK-MRT mit >1FL bewertet. „>1FL in der WS“ selektierte Hochrisikopatienten mit 75,8% 2-Jahres-Progressionsrate (2JPR), „>1FL im GK-MRT“ hingegen Patienten mit lediglich 46,7% 2JPR. Schlußfolgerungen Die Hälfte aller Untersuchungen mit >1FL im GK-MRT werden nicht korrekt mit „>1FL“ bewertet, wenn ein limitiertes Protokoll (WS oder WS+B) verwendet wird, was zu einer substantiellen Unterdiagnostizierung von Patienten mit Multiplem Myelom und folglich einem Ausbleiben der indizierten systemischen Therapie führt. Allerdings entspricht eher die Kombination von „>1FL in der WS“ als „>1FL im GK-MRT“ auf diesem Kollektiv der Anforderung, Hochrisikopatienten mit 80% 2JPR zu isolieren.

  • Open Access

    Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma

    by Maximilian Merz, Thomas Hielscher, David Schult, Elias K. Mai, Marc S. Raab, Jens Hillengass, Anja Seckinger, Dirk Hose, Martin Granzow, Anna Jauch, et al.


  • Open Access

    Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma

    by Maximilian Merz, Thomas Hielscher, Elias Karl Mai, Anja Seckinger, Dirk Hose, Anna Jauch, Sandra Sauer, Steffen Luntz, Uta Bertsch, Marc S. Raab, et al.


  • Open Access

    Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients

    by Seyed Hamidreza Mahmoudpour, Obul Reddy Bandapalli, Miguel Inácio da Silva Filho, Chiara Campo, Kari Hemminki, Hartmut Goldschmidt, Maximilian Merz, Asta Försti

    Based on the possible shared mechanisms of chemotherapy-induced peripheral neuropathy (CIPN) for different drugs, we aimed to aggregate results of all previously published genome-wide association studies (GWAS) on CIPN, and to replicate them within a cohort of multiple myeloma (MM) patients. Following a systematic literature search, data for CIPN associated single nucleotide polymorphisms (SNPs) with P-values< 10− 5 were extracted; these associations were investigated within a cohort of 983 German MM patients treated with bortezomib, thalidomide or vincristine. Cases were subjects that developed CIPN grade 2–4 while controls developed no or sub-clinical CIPN. Logistic regression with additive model was used. In total, 9 GWASs were identified from the literature on CIPN caused by different drugs (4 paclitaxel, 2 bortezomib, 1 vincristine, 1 docetaxel, and 1 oxaliplatin). Data were extracted for 526 SNPs in 109 loci. One hundred fourty-eight patients in our study population were CIPN cases (102/646 bortezomib, 17/63 thalidomide and 29/274 vincristine). In total, 13 SNPs in 9 loci were replicated in our population (p-value< 0.05). The four smallest P-values relevant to the nerve function were 0.0006 for rs8014839 (close to the FBXO33 gene), 0.004 for rs4618330 (close to the INTU gene), 0.006 for rs1903216 (close to the BCL6 gene) and 0.03 for rs4687753 (close to the IL17RB gene). Replicated SNPs provide clues of the molecular mechanism of CIPN and can be strong candidates for further research aiming to predict the risk of CIPN in clinical practice, particularly rs8014839, rs4618330, rs1903216, and rs4687753, which showed relevance to the function of nervous system.


  • Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance

    by Maximilian Merz, Thomas Hielscher, Korbinian Hoffmann, Anja Seckinger, Dirk Hose, Marc S. Raab, Jens Hillengass, Anna Jauch, Hartmut Goldschmidt


  • Open Access

    Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma

    by Maximilian Merz, Anna Jauch, Thomas Hielscher, Tilmann Bochtler, Stefan Olaf Schönland, Anja Seckinger, Dirk Hose, Uta Bertsch, Kai Neben, Marc Steffen Raab, et al.

    Key Points: Clonal heterogeneity detected by iFISH is common in newly diagnosed MM. Treatment with bortezomib overcomes the negative impact of high-risk cytogenetic abnormalities if no further subclones are detected.


  • Meeting report of the 6th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma

    by Maximilian Merz, Marc S. Raab, Hartmut Goldschmidt, Jens Hillengass

    The 6th Heidelberg Myeloma Workshop was held on May 5th and 6th, 2017 in the lecture hall of the University Hospital Heidelberg.